BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 30868576)

  • 41. Significance of histologic tumor grade in rectal cancer treated with preoperative chemoradiotherapy followed by curative surgery: A multi-institutional retrospective study.
    Song JH; Kim SH; Lee JH; Cho HM; Kim DY; Kim TH; Kim SY; Baek JY; Oh JH; Nam TK; Yoon MS; Jeong JU; Kim K; Chie EK; Jang HS; Kim JS; Kim JH; Kang KM
    Radiother Oncol; 2016 Feb; 118(2):387-92. PubMed ID: 26763136
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis : Oxaliplatin in neoadjuvant treatment for rectal cancer.
    De Felice F; Benevento I; Magnante AL; Musio D; Bulzonetti N; Caiazzo R; Tombolini V
    BMC Cancer; 2017 May; 17(1):325. PubMed ID: 28499428
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
    Bosset JF; Calais G; Mineur L; Maingon P; Stojanovic-Rundic S; Bensadoun RJ; Bardet E; Beny A; Ollier JC; Bolla M; Marchal D; Van Laethem JL; Klein V; Giralt J; Clavère P; Glanzmann C; Cellier P; Collette L;
    Lancet Oncol; 2014 Feb; 15(2):184-90. PubMed ID: 24440473
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma.
    Akbulut H; Altuntas F; Akbulut KG; Ozturk G; Cindoruk M; Unal E; Icli F
    Cytokine; 2002 Nov; 20(4):184-90. PubMed ID: 12543084
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of age on efficacy of postoperative oxaliplatin-based chemotherapy in patients with rectal cancer after neoadjuvant chemoradiotherapy.
    Huang XZ; Gao P; Song YX; Sun JX; Chen XW; Zhao JH; Ma B; Wang J; Wang ZN
    Oncotarget; 2016 Apr; 7(15):19643-53. PubMed ID: 26910371
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
    Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
    BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lymph node metastases in rectal cancer after preoperative radiochemotherapy: impact of intramesorectal distribution and residual micrometastatic involvement.
    Sprenger T; Rothe H; Becker H; Beissbarth T; Homayounfar K; Gauss K; Kitz J; Wolff H; Scheel AH; Ghadimi M; Rödel C; Conradi LC; Liersch T
    Am J Surg Pathol; 2013 Aug; 37(8):1283-9. PubMed ID: 23851331
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Absolute Lymphocyte Count in Preoperative Chemoradiotherapy for Rectal Cancer: Changes Over Time and Prognostic Significance.
    Oh SY; Heo J; Noh OK; Chun M; Cho O; Oh YT
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818780065. PubMed ID: 29909729
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Stage-to-stage comparison of preoperative and postoperative chemoradiotherapy for T3 mid or distal rectal cancer.
    Yeo SG; Kim DY; Park JW; Choi HS; Oh JH; Kim SY; Chang HJ; Kim TH; Sohn DK
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):856-62. PubMed ID: 21300482
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of body-mass index on treatment and outcome in locally advanced rectal cancer: A secondary, post-hoc analysis of the CAO/ARO/AIO-04 randomized phase III trial.
    Diefenhardt M; Ludmir EB; Hofheinz RD; Ghadimi M; Minsky BD; Fleischmann M; Fokas E; Rödel C
    Radiother Oncol; 2021 Nov; 164():223-231. PubMed ID: 34619239
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association between pathologic response in metastatic lymph nodes after preoperative chemoradiotherapy and risk of distant metastases in rectal cancer: An analysis of outcomes in a randomized trial.
    Bujko K; Michalski W; Kepka L; Nowacki MP; Nasierowska-Guttmejer A; Tokar P; Dymecki D; Pawlak M; Lesniak T; Richter P; Wojnar A; Chmielik E;
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):369-77. PubMed ID: 17118570
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Haemoglobin and creatinine values as prognostic factors for outcome of concurrent radiochemotherapy in locally advanced head and neck cancers : Secondary results of two European randomized phase III trials (ARO 95-06, SAKK 10/94).
    Ghadjar P; Pöttgen C; Joos D; Hayoz S; Baumann M; Bodis S; Budach W; Studer G; Stromberger C; Zimmermann F; Kaul D; Plasswilm L; Olze H; Bernier J; Wust P; Aebersold DM; Budach V
    Strahlenther Onkol; 2016 Aug; 192(8):552-60. PubMed ID: 27323753
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical Impact of Preoperative Albumin-Globulin Ratio in Patients with Rectal Cancer Treated with Preoperative Chemoradiotherapy.
    Toiyama Y; Oki S; Okugawa Y; Ide S; Yasuda H; Fujikawa H; Yoshiyama S; Hiro J; Ohi M; Inoue Y; Araki T; Kusunoki M
    Oncology; 2018; 95(5):270-280. PubMed ID: 29996133
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Predictive value of serum and tissue carcinoembryonic antigens for radiologic response and oncologic outcome of rectal cancer.
    Kim CH; Huh JW; Yeom SS; Kim HR; Kim YJ
    Pathol Res Pract; 2020 Mar; 216(3):152834. PubMed ID: 32001055
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adjuvant Chemotherapy in Rectal Cancer Patients Treated With Preoperative Chemoradiation and Total Mesorectal Excision: A Multicenter and Retrospective Propensity-Score Matching Study.
    Chung MJ; Lee JH; Lee JH; Kim SH; Song JH; Jeong S; Yu M; Nam TK; Jeong JU; Jang HS
    Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):438-448. PubMed ID: 30244158
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neutrophilia in locally advanced cervical cancer: A novel biomarker for image-guided adaptive brachytherapy?
    Escande A; Haie-Meder C; Maroun P; Gouy S; Mazeron R; Leroy T; Bentivegna E; Morice P; Deutsch E; Chargari C
    Oncotarget; 2016 Nov; 7(46):74886-74894. PubMed ID: 27713124
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Baseline Peripheral Blood Leukocytosis Is Negatively Correlated With T-Cell Infiltration Predicting Worse Outcome in Colorectal Cancers.
    Hu X; Li YQ; Li QG; Ma YL; Peng JJ; Cai SJ
    Front Immunol; 2018; 9():2354. PubMed ID: 30369930
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term prognostic impact of surgical complications in the German Rectal Cancer Trial CAO/ARO/AIO-94.
    Sprenger T; Beißbarth T; Sauer R; Tschmelitsch J; Fietkau R; Liersch T; Hohenberger W; Staib L; Gaedcke J; Raab HR; Rödel C; Ghadimi M
    Br J Surg; 2018 Oct; 105(11):1510-1518. PubMed ID: 29846017
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic Significance of Survivin Expression and Combined Analysis with Cancer Stem Cell and Epithelial-Mesenchymal Transition-related Markers in Patients with Rectal Cancer Undergoing Preoperative Chemoradiotherapy.
    Kim J; Ahn S; Kim K; Cho MS; Kim KH; Lee RA; Nam EM
    Anticancer Res; 2018 Dec; 38(12):6881-6889. PubMed ID: 30504405
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.
    Allegra CJ; Yothers G; O'Connell MJ; Beart RW; Wozniak TF; Pitot HC; Shields AF; Landry JC; Ryan DP; Arora A; Evans LS; Bahary N; Soori G; Eakle JF; Robertson JM; Moore DF; Mullane MR; Marchello BT; Ward PJ; Sharif S; Roh MS; Wolmark N
    J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26374429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.